Friday, Dec. 18, 2015, 77 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $24.26 to $4,955,373.00.

Highlighted Stocks Traded by Insiders:

Summer Infant (SUMR) - FREE Research Report

Almagor Dan, who is Director at Summer Infant, bought 30,000 shares at $1.95 on Dec. 18, 2015. Following this transaction, the Director owned 432,757 shares meaning that the stake was boosted by 7.45% with the 30,000-share transaction.

The shares most recently traded at $2.00, up $0.05, or 2.75% since the insider transaction. Historical insider transactions for Summer Infant go as follows:

  • 4-Week # shares bought: 52,371
  • 4-Week # shares sold: 34,954
  • 12-Week # shares bought: 74,340
  • 12-Week # shares sold: 34,954
  • 24-Week # shares bought: 259,411
  • 24-Week # shares sold: 34,954

The average volume for Summer Infant has been 36,800 shares per day over the past 30 days. Summer Infant has a market cap of $34.8 million and is part of the consumer goods sector and consumer non-durables industry. Shares are down 41.72% year-to-date as of the close of trading on Friday.

Summer Infant, Inc., together with its subsidiaries, designs, markets, and distributes branded juvenile health, safety, and wellness products primarily in North America. Currently, there are 3 analysts who rate Summer Infant a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SUMR - FREE

TheStreet Quant Ratings

rates Summer Infant as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full

Summer Infant Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cenveo (CVO) - FREE Research Report

Scheinmann Ian R, who is SVP, Legal Affairs at Cenveo, bought 5,000 shares at $1.12 on Dec. 18, 2015. Following this transaction, the SVP, Legal Affairs owned 107,959 shares meaning that the stake was boosted by 4.86% with the 5,000-share transaction.

The shares most recently traded at $1.01, down $0.11, or 10.89% since the insider transaction. Historical insider transactions for Cenveo go as follows:

  • 4-Week # shares bought: 122,000
  • 12-Week # shares bought: 122,000
  • 24-Week # shares bought: 247,811

The average volume for Cenveo has been 206,500 shares per day over the past 30 days. Cenveo has a market cap of $71.9 million and is part of the services sector and diversified services industry. Shares are down 52.38% year-to-date as of the close of trading on Friday.

Cenveo, Inc. provides print related products in the United States and internationally. It operates through three segments: Envelope, Print, and Label and Packaging. Currently, there are 3 analysts who rate Cenveo a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVO - FREE

TheStreet Quant Ratings

rates Cenveo as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins. Get the full

Cenveo Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Arqule (ARQL) - FREE Research Report

Loberg Michael D, who is Director at Arqule, bought 3,719 shares at $2.16 on Dec. 18, 2015. Following this transaction, the Director owned 132,142 shares meaning that the stake was boosted by 2.9% with the 3,719-share transaction.

The shares most recently traded at $2.22, up $0.06, or 2.73% since the insider transaction. Historical insider transactions for Arqule go as follows:

  • 4-Week # shares bought: 11,231
  • 12-Week # shares bought: 11,231
  • 24-Week # shares bought: 11,231

The average volume for Arqule has been 176,900 shares per day over the past 30 days. Arqule has a market cap of $134.6 million and is part of the health care sector and drugs industry. Shares are up 68.03% year-to-date as of the close of trading on Friday.

ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases. Currently, there are no analysts who rate Arqule a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARQL - FREE

TheStreet Quant Ratings

rates Arqule as a

sell

. The area that we feel has been the company's primary weakness has been its meager revenue growth. Get the full

Arqule Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.